PH26291A - Oxetanones - Google Patents

Oxetanones Download PDF

Info

Publication number
PH26291A
PH26291A PH33205A PH33205A PH26291A PH 26291 A PH26291 A PH 26291A PH 33205 A PH33205 A PH 33205A PH 33205 A PH33205 A PH 33205A PH 26291 A PH26291 A PH 26291A
Authority
PH
Philippines
Prior art keywords
pyran
tetrahydro
hexyl
hydroxy
formyl
Prior art date
Application number
PH33205A
Other languages
English (en)
Inventor
Pierre Dr Barbier
Fernand Dr Schneider
Ulrich Widmer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PH26291A publication Critical patent/PH26291A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12Beta-lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyesters Or Polycarbonates (AREA)
PH33205A 1984-12-21 1985-12-18 Oxetanones PH26291A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH610284 1984-12-21
CH393485 1985-09-12

Publications (1)

Publication Number Publication Date
PH26291A true PH26291A (en) 1992-04-10

Family

ID=25694219

Family Applications (1)

Application Number Title Priority Date Filing Date
PH33205A PH26291A (en) 1984-12-21 1985-12-18 Oxetanones

Country Status (20)

Country Link
US (2) US4931463A (cs)
EP (1) EP0185359B1 (cs)
CN (1) CN1012643B (cs)
AT (1) ATE70061T1 (cs)
AU (1) AU583569B2 (cs)
CA (1) CA1270837A (cs)
CS (1) CS262425B2 (cs)
DE (1) DE3584829D1 (cs)
DK (1) DK166724B1 (cs)
DO (1) DOP1985004386A (cs)
FI (1) FI91403C (cs)
HU (1) HU200172B (cs)
IE (1) IE58926B1 (cs)
IL (1) IL77338A (cs)
MC (1) MC1728A1 (cs)
NO (1) NO171160C (cs)
NZ (1) NZ214565A (cs)
PH (1) PH26291A (cs)
PT (1) PT81748B (cs)
ZW (1) ZW20385A1 (cs)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
US4895973A (en) * 1986-08-14 1990-01-23 G. D. Searle & Company Substituted glutaric acid lactones in the treatment of hyperlipidemia
US4806564A (en) * 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4816477A (en) * 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
CA2035972C (en) * 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5260310A (en) * 1990-02-26 1993-11-09 Hoffmann-La Roche Inc. Oxetanone compounds and pharmaceutical compositions containing them
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
NZ336755A (en) * 1997-02-05 2001-06-29 F Use of gastrointestinal lipase inhibitors in particular tetrahydrolipstatin (orlistat)
KR100510614B1 (ko) * 1997-04-15 2005-08-30 씨에스아이알 식욕 억제 활성을 갖는 화합물의 제조를 위한 중간체 및이의 제조 방법
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
CA2358921A1 (en) * 1999-10-29 2001-05-10 John Jason Gentry Mullins Oxetanone derivatives
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
JP4772264B2 (ja) * 2000-07-28 2011-09-14 エフ.ホフマン−ラ ロシュ アーゲー リパーゼ阻害物質の新規用途
AU2002212120B2 (en) 2000-08-09 2006-05-11 Cheplapharm Arzneimittel Gmbh Lipase inhibitors for the treatment of dyspepsia
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US6392061B1 (en) * 2000-10-16 2002-05-21 Zpro Chemical, Inc. Process for making (2S, 3S, 5S) oxetanone derivatives
CA2422698C (en) 2000-10-16 2009-12-15 F. Hoffmann-La Roche Ag Indoline derivatives and their use as 5-ht2 receptor ligands
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
KR100539143B1 (ko) 2000-12-27 2005-12-26 에프. 호프만-라 로슈 아게 인돌 유도체 및 그의 5-ht2b 및 5-ht2c 수용체리간드로서의 용도
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
DE60225274T2 (de) 2001-05-21 2009-03-26 F. Hoffmann-La Roche Ag Chinolinderivate als liganden für den neuropeptid-y-rezeptor
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
CN100383124C (zh) 2002-02-04 2008-04-23 霍夫曼-拉罗奇有限公司 作为npy拮抗剂的喹啉衍生物
RU2004129285A (ru) 2002-02-28 2005-10-27 Ф.Хоффманн-Ля Рош Аг (Ch) Производные тиазола в качестве антагонистов рецептора npy
US7728153B2 (en) 2002-04-17 2010-06-01 The Burnham Institute For Medical Research Method for the asymmetric synthesis of beta-lactone compounds
WO2003088975A1 (en) * 2002-04-17 2003-10-30 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
RU2296757C2 (ru) 2002-07-05 2007-04-10 Ф.Хоффманн-Ля Рош Аг Производные хиназолина
CN100381429C (zh) 2002-08-07 2008-04-16 霍夫曼-拉罗奇有限公司 噻唑衍生物
RU2296759C2 (ru) 2002-09-12 2007-04-10 Ф.Хоффманн-Ля Рош Аг N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты)
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
ES2312819T3 (es) 2002-11-25 2009-03-01 F. Hoffmann-La Roche Ag Derivados de indolilo.
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
WO2005005403A2 (en) * 2003-07-15 2005-01-20 Ranbaxy Laboratories Limited Process for preparation of oxetan-2-ones
CA2533464A1 (en) 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Thiazole derivatives as npy antagonists
CN100422179C (zh) 2003-08-12 2008-10-01 霍夫曼-拉罗奇有限公司 2-氨基-5-苯甲酰基噻唑npy拮抗剂
US7074822B2 (en) * 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
DE102004009076A1 (de) * 2004-02-23 2005-10-27 Solvay Pharmaceuticals Gmbh Alkylcarbamat-substituierte β-Lactone, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US7121355B2 (en) * 2004-09-21 2006-10-17 Cnh America Llc Bulldozer autograding system
WO2006035296A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Process for the preparation of an orlistat derivative useful as reference standard in the determination of the purity of orlistat and process for the preparation of orlistat
JP2008540368A (ja) 2005-05-03 2008-11-20 エフ.ホフマン−ラ ロシュ アーゲー 5−ht2リガンドとしての四環式アザピラジノインドリン
ATE430744T1 (de) 2005-08-18 2009-05-15 Hoffmann La Roche Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
US20090171104A1 (en) * 2005-10-05 2009-07-02 Killol Patel Process for the preparation of orlistat
BRPI0619266A2 (pt) 2005-11-30 2011-09-27 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, obesidade, diabetes do tipo ii e seu uso
KR101124156B1 (ko) 2005-11-30 2012-03-23 에프. 호프만-라 로슈 아게 1,5-치환된 인돌-2-일 아마이드 유도체
CA2630270A1 (en) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives
AU2006324089A1 (en) 2005-12-09 2007-06-14 F. Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
KR20080068127A (ko) 2005-12-15 2008-07-22 에프. 호프만-라 로슈 아게 피롤로[2,3-c]피리딘 유도체
CN101331131A (zh) 2005-12-16 2008-12-24 霍夫曼-拉罗奇有限公司 用作H3受体调节剂的吡咯并[2,3-b]吡啶衍生物
JP2009523150A (ja) * 2006-01-13 2009-06-18 エフ.ホフマン−ラ ロシュ アーゲー シクロヘキシルピペラジニルメタノン誘導体及びh3受容体調節剤としてのそれらの使用
CN101370779B (zh) * 2006-01-23 2011-07-20 霍夫曼-拉罗奇有限公司 具有h3受体活性的环己基磺酰胺衍生物
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
CN101448820A (zh) * 2006-05-30 2009-06-03 霍夫曼-拉罗奇有限公司 哌啶基嘧啶衍生物
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
WO2008149321A2 (en) * 2007-06-06 2008-12-11 Ranbaxy Laboratories Limited Process for the preparation of orlistat
CN101796043A (zh) 2007-07-25 2010-08-04 霍夫曼-拉罗奇有限公司 苯并呋喃-和苯并[b]噻吩-2-羧酸酰胺衍生物及其作为阻胺3受体调节剂的应用
JP2011502167A (ja) * 2007-10-31 2011-01-20 バーンハム インスティテュート フォー メディカル リサーチ β−ラクトン化合物
US8993509B2 (en) 2009-03-31 2015-03-31 Robert Zimmerman Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
SG11202000239XA (en) 2017-07-12 2020-02-27 Mayo Found Medical Education & Res Compounds for the reducing lipotoxic damage
CN112079821A (zh) * 2020-09-14 2020-12-15 中山万汉制药有限公司 奥利司他与苯氨基嘧啶类化合物形成的缀合物及其制备方法与用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2478388A (en) * 1945-09-28 1949-08-09 Eastman Kodak Co beta-lactones from unsaturated aldehydes and unsaturated ketones
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
GB2023604B (en) * 1978-05-25 1982-07-28 Microbial Chem Res Found Physiologically active derivatives of esterastin and production thereof
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives

Also Published As

Publication number Publication date
FI854797A0 (fi) 1985-12-04
CN1012643B (zh) 1991-05-22
PT81748B (pt) 1988-07-29
AU5125985A (en) 1986-06-26
MC1728A1 (fr) 1986-12-15
FI91403B (fi) 1994-03-15
AU583569B2 (en) 1989-05-04
HUT39440A (en) 1986-09-29
NO171160B (no) 1992-10-26
PT81748A (en) 1986-01-02
CN85108888A (zh) 1986-07-09
IL77338A (en) 1991-04-15
HU200172B (en) 1990-04-28
US5175186A (en) 1992-12-29
DOP1985004386A (es) 1991-04-20
DK600385D0 (da) 1985-12-20
IE58926B1 (en) 1993-12-01
EP0185359A2 (de) 1986-06-25
FI854797A7 (fi) 1986-06-22
DK166724B1 (da) 1993-07-05
EP0185359B1 (de) 1991-12-04
ZW20385A1 (en) 1986-03-05
NO855213L (no) 1986-06-23
NZ214565A (en) 1989-06-28
DE3584829D1 (de) 1992-01-16
CA1270837A (en) 1990-06-26
DK600385A (da) 1986-06-22
IE853277L (en) 1986-06-21
EP0185359A3 (en) 1987-08-26
FI91403C (fi) 1994-06-27
US4931463A (en) 1990-06-05
CS262425B2 (en) 1989-03-14
NO171160C (no) 1993-02-03
ATE70061T1 (de) 1991-12-15

Similar Documents

Publication Publication Date Title
PH26291A (en) Oxetanones
US5246960A (en) Oxetanones
Clive et al. Total synthesis of both (+)-compactin and (+)-mevinolin. A general strategy based on the use of a special titanium reagent for dicarbonyl coupling
US4983746A (en) Oxetanones and process for their production
US3950406A (en) Hydroxylated 15-deoxy derivatives of 9-hydroxy-13-trans-prostenoic acid
WO1995033716A1 (en) Vitamin d3 derivative and process for producing the same
Rojo et al. Stereoselective synthesis of substituted γ-butyrolactones from γ-hydroxy-α, β-unsaturated phenyl sulfones
EP0778269B1 (en) Prostaglandins and process for producing the same
DE2629644A1 (de) 16,16-spirocycloalkylprostaglandine und verfahren zu ihrer herstellung
KR950008310B1 (ko) 옥세타논의 제조방법
Domínguez et al. Flexible and stereoselective construction of polypropionate chains from enantiomerically pure γ-hydroxy-α, β-unsaturated sulfones
US4359581A (en) Process for the production of caracyclin intermediates
US4665080A (en) Imidazolyl compounds and their use as medicaments
US5102793A (en) Stereospecific keto reduction of bicyclooctandione-carboxylic acid esters by microorganisms
USRE29469E (en) Hydroxylated 15-deoxy derivatives of 9-hydroxyl-13-trans-prostenoic acid
US5216177A (en) Method of preparing trans-3,4-disubstituted-γ-lactones
GB2270914A (en) HIV protease inhibitor compounds
US4526991A (en) 2,6-Dioxa-bicyclo-[2,2,2]-octane-7-yl-acetaldehydes
US4107441A (en) Novel 16 hydroxy 15-deoxy-5-cis-prostenoic acids and esters
US4005106A (en) 3β-[(Methoxalyl)oxy]-2α-(3-oxo-1-octenyl)-5-oxo-1β-cyclopentaneheptanoic acid and process
HU192316B (en) Process for producing new carbacyclin derivatives and pharmaceutical compositions containing them
US3992412A (en) 2α-(2-Carboxy-2-oxoethyl)-3β-hydroxy-5-oxo-1β-cyclopentaneheptanoic acid and process
US4179451A (en) Novel hydroxy substituted 15-deoxy-5-cis-prostenoic acids and esters
JPH03220158A (ja) 光学活性カルバサイクリン誘導体の製造方法
JPH0645575B2 (ja) 3―メチレン―2,6,7―三置換ビシクロ[3.3.0オクタン類